Human adenovirus (AdV) infection and EBV-lymphoproliferative disease (LPD) are serious complications following allogeneic stem cell transplantation. In the healthy individual these viruses cause minor, self-limiting diseases but in the immunocompromised patient they are responsible for significant morbidity and mortality 
marrow or peripheral stem cell transplantation (SCT). 1, 2 In the normal host, both of these viruses cause minor, selflimiting diseases but in the immunocompromised patient, they are responsible for significant morbidity and mortality. In a retrospective analysis of 206 patients who received a T cell-depleted allogeneic bone marrow transplant (BMT) from an HLA matched or mismatched unrelated donor, 19% were found to shed AdV in their stool or urine. Thirteen of these patients had clinical symptoms of AdV infection and seven died of disseminated disease. 2 Although little is known about the cellular immune response to AdV in humans, the association between severe AdV infection and immunosuppression strongly suggests that normally AdV is controlled by the cellular arm of the immune response.
After a T cell-depleted transplant, the risk of developing EBV-induced LPD can range from 12% to 25%, depending upon the patient's state of immunosuppression. [3] [4] [5] [6] In these patients, cellular immunity is severely compromised as a result of immunosuppressive treatment which is aimed at preventing graft-versus-host disease and graft rejection. In SCT patients, who are most susceptible to developing this complication between 60 and 90 days post transplant, there is a correlation between the peak incidence of EBV-LPD and the levels of EBV-specific cytotoxic T lymphocytes (CTLs) in their peripheral blood. 7 Therefore, the restoration of cellular immunity is critical to prevent both AdV and EBV reactivation. 8, 9 Although there are drugs available to treat AdV and EBV infections, these medications have limiting side-effects and, in serious infections, they have little chance of controlling virus proliferation. Clinically, the approach of adoptively transferring EBV-specific CTLs to patients post T celldepleted transplant, has proven to be safe and highly efficacious both for the prophylaxis and treatment of EBV-LPD. [8] [9] [10] The polyclonal gene-marked CTLs used in these studies were shown to expand significantly in vivo and both CD8 + and CD4 + T cells were demonstrated to persist for more than 18 months. [8] [9] [10] To expand such CTL lines in vitro, donor-derived B-LCLs, which had been latently infected with EBV, were co-cultured with donor PBMNCs for several weeks. B-LCLs are capable of presenting antigen in the context of both HLA class I and class II molecules 11 and their use as APCs to stimulate both proliferative 12 and cytotoxic responses [8] [9] [10] has also been extensively described.
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To date, there have only been two publications demonstrating that it is possible to generate, in vitro, CTLs directed against AdV. 13, 14 To expand these T cell lines, autologous dendritic cells (DCs) were infected with AdV and subsequently co-cultured with autologous PBMNCs in the presence of low-dose IL-2. Importantly, the AdV-specific CTLs generated in this way were shown to have extensive cross-reactivity in that CTLs generated using an AdV5 virus also lysed target cells infected with AdV11, AdV4 or AdV18.
14 Such cross-reactivity is important as it indicates that the adoptive transfer of CTLs generated in vitro against one AdV serotype may protect immunocompromised patients from infections by AdV of all serotypes.
Therefore, it is clear that both AdV and EBV pose significant problems for transplant patients. Hence, the development of therapies which restore immunity to these viruses is of great interest. The aims of this study were two-fold: first, to modify and refine the DC methodology available for generating monospecific CTLs recognizing AdV; and second to develop a novel system whereby AdV and EBV-specific CTLs could be expanded simultaneously in vitro. To generate AdV-specific CTLs, we infected immature DCs, which had been generated in the absence of serum, with an E1A/E3-deleted AdV5 virus in the presence of a lipid reagent. We demonstrate that these infected DCs are capable of stimulating CTLs which have AdVspecific cytotoxicity and that this cytotoxicity is mediated by both CD8 + and CD4 + T cells. To simultaneously expand bispecific CTL populations, B-LCL which had been co-cultured on a CD40 ligand-expressing monolayer were infected with an E1A/E3-deleted AdV5 virus and then used to prime autologous PBMNCs. We demonstrate that CTL lines generated by this methodology have both EBV and AdV specificity which is mediated predominantly by CD8 + T cells but also contains a cytotoxic CD4 + fraction.
Materials and methods

Serum-free culture of dendritic cells
In this study we used either peripheral blood mononuclear cells (PBMNCs) or buffy coats from healthy, EBV and AdV-seropositive donors. PBMNCs were obtained from heparinized peripheral blood by Ficoll-Hypaque (Biochrom, Berlin, Germany) density gradient centrifugation. The mononuclear cell fraction was washed twice with Dulbecco's phosphate-buffered saline (Dulbecco's-PBS; Cellconcepts, Umkirch, Germany) and resuspended in RPMI-1640 medium (Cellconcepts) at 5 × 10 6 cells per well using six-well plates (Peske OHG, Aindling-Pichl, Germany). The plates were incubated at 37°C and 5% CO 2 for 2 h, then the non-adherent cells were decanted. The adherent cells were cultured in 2 ml/well of serum-free medium (X-VIVO-15; BioWhittaker, Walkersville, MD, USA), supplemented with 2 mm l-glutamine (GIBCO-BRL, Karlsruhe, Germany), penicillin-streptomycin (100 U/ml and 100 g/ml respectively, GIBCO-BRL) and 800 IU/ml rhGM-CSF (Essex Pharma, Munich, Germany) and 500 IU/ml rhIL-4 (Hölzel Diagnostika, Cologne, Germany). After 7 days, fresh rhGM-CSF (800 IU/ml) was added to the wells and after 10-12 days of culture the DCs were harvested for further experiments.
Phenotypic analysis
For characterization of DCs, the following monoclonal antibodies (mAB), conjugated with either fluorescein isothiocyanate (FITC) or phycoerythrin (PE), were used: CD1a, CD11c, CD11a, CD123, CD25, CD40 (Pharmingen, Hamburg, Germany), CD80, CD86, CD51, HLA-ABC, HLA-DR, CD19 (all from Hölzel Diaknostika), CD83 (Immunotech-Coulter, Marseille, France) and CD14 (DAKO Diagnostika, Hamburg, Germany). Dual immunofluorescence staining was performed by standard techniques. The cells were analyzed using a FACS Calibur flow cytometer and CellQuest software (Becton Dickinson, Mountain View, CA, USA).
EBV-transformed B cell lines (LCL)
B95-8 transformed LCLs were established using published techniques.
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Adenovirus infection
A recombinant E1A/E3-deleted adenovirus type 5 (Ad5-CMV-GFP) containing the green fluorescence protein under the control of the immediate-early CMV promoter, was purchased from Quantum Biotechnologies (Montreal, Canada). The same virus without GFP was also purchased from Quantum Biotechnologies. Both adenoviruses were provided at a titer of 6.3 ϫ 10 9 infectious particles/ml. For infection of human DCs, Ad5-CMV-GFP was diluted by suspending 7.5 ϫ 10 7 (50 infectious particles per cell) in 50 l of serum-free medium (OptiMem; GIBCO BRL). Meanwhile, 1.25 g of lipofectamine (GIBCO) was diluted in 50 l of SFM. These virus and liposome solutions were mixed together and incubated at room temperature for 15 min. The DCs (1.5 ϫ 10 6 per experiment) were harvested, washed and resuspended in 100 l SFM. The cells were then combined with the 100 l of virus/liposome solution and incubated for 60 min at 37°C in the incubator. After incubation, the cells were washed and resuspended at 5 ϫ 10 5 cells/ml in SFM (X-VIVO-15) supplemented with 400 U/ml rhGM-CSF and 200 U/ml rhTNF-␣ (R&D Systems, Wiesbaden, Germany). The cells were incubated at 37°C for 48-72 h prior to use. For experiments without lipid the adenovirus was resuspended in SFM alone and then added to the cells in a total volume of 200 l per 1.5 ϫ 10 6 cells. The duration of infection was the same as with lipid.
For Ad5-CMV-GFP infection of LCLs, an MOI of 100 was used in the absence of lipids. LCLs were harvested, washed and resuspended in SFM (100 l per 1 × 10 6 cells) and combined with the adenovirus in a total volume of 200 l. The cells were then incubated for 2 h at 37°C and 5% CO 2 . After incubation, the cells were centrifuged, the supernatant removed, and the cells resuspended at 1 ϫ 10 6 cells/ml in complete medium for 24-48 h before being harvested for further experiments.
Co-culturing of LCLs on a CD40 ligand monolayer
In order to upregulate the ␣ 5 ␤ 3 -integrin receptor (CD51) on the surface of LCLs, a CD40-CD40 ligand co-culturing system was developed using a murine fibroblast cell line which had been stably transfected with the human CD40 ligand gene (L-CD40L cells kindly provided by J Banchereau, Dardilly, France). For cross-linking experiments, L-CD40L cells were plated at 5 ϫ 10 5 cells per well of a sixwell plate in 2 ml of complete RPMI-1640 medium. At Ͼ80% confluence these cells were irradiated (6000 rad) and washed with PBS. LCLs were then seeded on to the irradiated L-CD40L cells at 5 ϫ 10 5 cells per well in 2 ml of complete medium and incubated for 72 h at 37°C and 5% CO 2 . Post stimulation, the LCLs were gently removed from the L-CD40L monolayer, washed and then infected with the Ad5-CMV-GFP virus for use in subsequent experiments.
Detection and blocking of CD51 expression and modification of its expression by TNF-␣
To assess surface CD51 expression, the LCLs were stained both before and after co-culturing on the L-CD40L cells with a PE-conjugated anti-CD51 mAb (Diaclone; Hölzel Diaknostika). Immunofluoresence was analyzed using a FACS Calibur flow cytometer and CellQuest software.
To assess the influence of TNF-␣ on CD51 expression, immature DCs were cultured for 48-72 h either with or without rhTNF-␣ (100-500 U/ml) and CD51 expression was then analyzed by staining with the antibody as described above.
For the CD51-blocking experiments, immature DCs were harvested and incubated for 30 min with 20 g/ml of an unconjugated mAB against CD51 prior to infection with the Ad5-CMV-GFP.
Mixed lymphocyte reaction (MLR)
T lymphocytes were isolated from PBMNCs by using negatively selected magnetic bead separation following the manufacturer's instructions (Miltenyi Biotech, Bergisch Gladbach, Germany). Purified T cells (either allogeneic or autologous) were seeded into 96-well round-bottomed microplates (NUNC, Wiesbaden, Germany) at 1 ϫ 10 5 cells/well. Irradiated (3000 rad) ADV infected and uninfected DCs or ADV infected and uninfected LCLs (irradiated at 5000 rad) were added to the T cells at varying ratios in triplicate wells. The final volume of each well was adjusted to 200 l with complete medium. Triplicate wells of T cells alone were use as the background control. After 6 days of culture, 1 Ci of methyl-3 H-thymidine (Amersham Life Science, Buckinghamshire, UK) was added to each well and incubation was continued for an additional 18 h. Cells were collected on to Unifilter plates (Canberra-Packard, Dreieich, Germany) using a FilterMate Cell Harvester (Canberra-Packard) and thymidine uptake was quantitated by liquid scintillation in a Packard Topcounter (Canberra-Packard).
Phenotypic analysis of the proliferating T cells in the MLR was analyzed by flow cytometry using mAbs against CD3, CD4, CD8 and CD56.
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Soluble antigen-presentation assay ADV infected and uninfected DCs or ADV infected and uninfected LCLs were suspended in complete medium containing 20 mg/ml recombinant tetanus toxin (TT) fragment C (Chiron Behring, Marburg, Germany) or complete medium alone and incubated overnight at 37°C. The cells were then irradiated and placed in triplicate wells of a 96-well plate at various T:Stimulator ratios. Purified autologous T lymphocytes, prepared as above, were added to the stimulators at 10 5 cells/well in a final volume of 200 l complete medium, and incubated for 5 days. 1 Ci of methyl-3 H-thymidine was added to each well and incubation was continued for an additional 18 h. Thymidine uptake was quantitated as described above.
ADV-specific CTL lines
ADV-specific CTLs were generated by co-culturing 2 ϫ 10 6 /ml PBMNC with 5 ϫ 10 4 /ml autologous ADV infected dendritic cells in complete RPMI-1640 medium. After 9 days of culture, the cells were harvested and sub-cultured in 24-well plates at 1 ϫ 10 6 per well and re-stimulated at a ratio of 4:1 with 2.5 ϫ 10 5 autologous ADV infected DCs. After 16 days of culture, the lines were superexpanded using autologous irradiated (5000 rad) LCLs and IL-2 (20 U/ml, three times a week). After 28-35 days of culture, the cytotoxicity of each line was assessed using chromium release assays.
Simultaneous expansion of CTLs recognizing both AdV and EBV
In order to generate polyclonal CTLs which recognized both EBV and ADV, ADV infected LCL were used as a single stimulator cell. PBMNC 2 ϫ 10 6 were co-cultured with 5 ϫ 10 4 autologous irradiated (5000 rad) ADV infected LCLs in complete RPMI-1640 medium. After 9 days of culture, the cells were harvested and subcultured in 24-well plates at 2 ϫ 10 6 per well and restimulated at a ratio of 4:1 with 5 ϫ 10 5 autologous irradiated ADV infected LCLs. After an additional 5 days of culture, 20 U/ml rhIL-2 was added and the developing CTLs were restimulated every 7 days at a ratio of 4:1 using uninfected, irradiated LCLs. After another 28-35 days in culture the cytotoxicity of each line was assessed.
Chromium release assays
The cytotoxicity of each CTL line was analyzed using a standard 4 h chromium-51 release assay using a range of effector:target ratios. In the monospecific assays the target cells included autologous, uninfected and ADV infected dendritic cells, allogeneic (HLA-mismatched) uninfectedand ADV infected dendritic cells, autologous and allogeneic LCLs, and the T cell line HSB-2 which is sensitive to killing by CD56-positive natural killer cells. In the 'bispecific' assays the target cells included autologous ADV infected and uninfected DCs, autologous LCLs, allogeneic LCLs, allogeneic ADV infected and uninfected DCs and HSB-2. To determine whether cytolysis was restricted by HLA class I or class II, target cells were preincubated for 30 min with 20 g/ml of W6/30 (DAKO), a monoclonal antibody that recognizes a monomorphic HLA class I determinant or CR3/43 (DAKO), which recognizes HLA-DR, -DP and -DQ and blocks HLA class II-restricted killing.
Results were expressed as % of specific lysis according to the following formula Experimental release − spontaneous release Maximum release − spontaneous release × 100
Experimental release represents c.p.m. released from the target cells incubated with the effector cells; spontaneous release is that from target cells alone and maximum release is c.p.m. released from target cells after incubation with 2% Triton X-100 (Sigma, Deisenhofen, Germany).
Immunophenotyping
For cell surface phenotyping, the CTLs were incubated with combinations of FITC-or PE-conjugated monoclonal antibodies to CD3, CD4, CD8, CD56, CD16, CD25, HLA-DR, TCR-␣␤ or TCR-␥␦. Cells were analyzed on a FACScan flow cytometer.
Results
All of the donors used in this study (n = 18) were both EBV and AdV-seropositive.
Infection of immature DCs by recombinant adenovirus
Dendritic cells were cultured under serum-free conditions, using established techniques. After 10-12 days in culture, approximately 45 Ϯ 15% of the non-adherent cells displayed typical DC morphology with large cell bodies, lobular nuclei and numerous fine, motile cytoplasmic projections (data not shown). After 12 days, the DCs were stained with specific monoclonal antibodies to assess the expression of the typical DC surface markers ( Figure 1a) . DCs generated by this procedure were classified as being immature as they expressed little or no CD83, a marker expressed on mature DCs, and low to intermediate levels of CD1a, HLA-ABC and -DR, CD86, CD54, CD11c and CD40. CD51 (integrin ␣ 5 ␤ 3 ) which is important for the internalization of adenovirus, was expressed at significant levels and CD14 and CD19 expression was negative. In order to mature these DCs, they were cultured in TNF-␣ (200 U/ml) for 72 h and then the immunophenotyping was repeated. Now the cells expressed higher levels of HLA-DR, HLA-ABC, CD86, CD40, CD54 and CD83 (Figure 1b) . Although the cells still expressed CD1a and CD11c, the level of expression of these markers was reduced as was expression of CD51.
First, we compared the capacity of both immature and mature DCs to be transfected with the AdV-GFP at a range of MOIs from 20 to 1000 (data not shown) in the presence or absence of the lipid reagent, lipofectamine. As shown in Figure 2a As mature DCs are known to be more immunostimulatory than immature DCs, and one of the aims of this study was to generate specific CTL responses, we opted to infect immature DCs at an MOI of 50 in the presence of lipid, and then to mature these infected DCs for an additional 48 h with TNF-␣ before use in further experiments. Therefore, to determine whether cells expressing GFP were mature, we analyzed CD83, CD86 and HLA-DR fluorescence, respectively, vs GFP fluorescence (Figure 2b ). Of CD83 + cells, Ͼ55% expressed GFP, of HLA-DR + cells, Ͼ90% expressed GFP and Ͼ55% of cells expressing CD86 were also positive for GFP. Therefore, DCs expressing the markers of maturity were also positive for GFP.
Effect of TNF-␣ on CD51 expression in DCs
Our results are in accordance with others showing that mature DCs are less susceptible to AdV transfection than immature DCs. One of the possible reasons for this is that immature DCs express CD51 at higher levels than mature DCs. In order to determine whether the dose of TNF-␣ used in maturing the DCs had any effect on CD51 expression, immature DCs were incubated for 48-72 h in the presence of increasing doses (0-500 U/ml) of TNF-␣ and then the cells were stained for CD51. As shown in Figure 3a , the effect of TNF-␣ on CD51 expression was dose-dependent and at 200 U/ml which is the dose we used to mature the DCs, less than 11% of the DCs expressed CD51. In contrast, Ͼ52% of DCs not treated with TNF-␣ stained positive for CD51 (P Ͻ 0.005).
To confirm that CD51 on immature DCs is involved in AdV transfection, we performed CD51 blocking experiments using a monoclonal antibody against the CD51 antigen. Immature (day 10) DCs were incubated for 30 min with an anti-CD51 antibody and then infected with AdV-GFP at an MOI of 50 in the presence of lipofectamine. Forty-eight hours later, the cells were analyzed for GFP expression using flow cytometry. In the presence of the anti-CD51 antibody, both the percentage of infected DCs was decreased significantly (from a mean of 92 Ϯ 2.5% to 48.5 Ϯ 5.5%, P Ͻ 0.0001) as well as the MFI of GFP expression (from a median of 353.1 to 48.1 fluorescent units, P Ͻ 0.005) and an example is shown in Figure 3b .
Adenovirus infected, mature DCs are highly immunostimulatory in MLR assays
In order to confirm that mature transfected DCs still had immunostimulatory capacity, MLRs were set up in which 1 × 10 5 purified, HLA-mismatched T cells from AdV-seropositive donors were co-cultured with varying numbers of irradiated infected or uninfected DCs. As illustrated in Figure 4 , uninfected DCs did show a significant capacity to stimulate T cell proliferation, however, AdV-transfected DCs stimulated the T lymphocytes much more efficiently at all T:DC ratios tested (P Ͻ 0.005).
Phenotypically, the proliferating T cells were predominantly CD4
+ in both infected and uninfected groups but
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Infected DCs are potent presenters of exogenous antigen
AdV infected DCs were compared with uninfected DCs for their capacity to uptake, process and present tetanus toxoid to autologous, purified T lymphocytes. As shown in Figure  5 , at all of the T:DC ratios tested, AdV infected DCs stimu- lated the proliferation of autologous T cells significantly better than uninfected DCs plus TT (P Ͻ 0.0001) or uninfected DCs minus TT (P Ͻ 0.0001).
Phenotypically, the proliferating T cells were predominantly CD4 + in both infected and uninfected groups but there was also a significant proportion of CD8 + T cells in both groups ( Figure 5 ) and no CD56 + NK cells.
Adenovirus infected mature DCs stimulate an AdVspecific CTL response
For induction of an adenovirus-specific CTL response, AdV infected mature DCs were used as stimulators and autolog- ous PBMNCs were used as responder cells. After three weekly stimulations, the CTL lines were tested for specificity using 4 h chromium release assays and a range of E:T ratios (5:1 to 40:1). As targets we used AdV infected autologous DCs, uninfected DCs, HLA-mismatched DCs, both infected and uninfected, allogeneic LCL and HSB-2 which is a cell line susceptible to natural killer (NK) cell lysis. As shown in Figure 6a , the low reactivity of DCstimulated T cells against all of the targets (Ͻ10% at an E:T ratio of 40:1), with the exception of AdV infected autologous DC (59.3 Ϯ 6.6% at an E:T ratio of 40:1), indicates that the CTL lines were AdV specific. In addition, the minimal killing of the HSB-2 cell line indicates that the level of MHC-unrestricted killing was low in this system.
The predominance of MHC-restricted killing was further confirmed using monoclonal antibodies to either HLA class I or class II on the surface of the target cells. Figure 6b illustrates that the addition of a pan HLA-ABC antibody reduced the level of specific lysis of the AdV infected DCs, from 54% to 32% at an E:T ratio of 40:1, whilst the addition of an antibody directed against HLA-DR reduced the specific killing from 54% to 20% at an E:T ratio of 40:1. In order to exclude a non-specific effect of the blocking antibodies, a mouse IgG2a isotype control was used. The addition of this antibody did not result in inhibition of lysis, confirming the specificity of the blocking Abs (data not shown). Phenotypic analysis of the CTL lines confirmed that there was a predominance of CD4 + T cells (62.6 Ϯ 11.7%) but also some CD8 + T cells (13.6 Ϯ 5.2%) and no CD56 + T cells.
Enhanced infection of LCLs which have been co-cultured on CD40 ligand-expressing monolayers
To simultaneously expand specific T cells which recognized both EBV and AdV-expressing targets, we first optimized the infection of LCLs using a CD40 ligand-based co-culture system. LCLs were seeded on to irradiated monolayers of L cells, which had been engineered to express the human CD40 ligand, for 72 h at a ratio of 1:1. The LCLs were then removed from the monolayer and infected with the AdV-GFP at an MOI of 50-100 for 2 h. Fortyeight hours post infection, the cells were analyzed for GFP fluorescence using flow cytometry. As shown in Figure 7a , infected LCLs which had not been pre-stimulated by CD40L crosslinking, were generally poorly infected and from the nine representative LCLs shown, only two of them were Ͼ10% positive. By contrast, when the same LCLs were cross-linked via CD40, there was a significant improvement in their infection capacity and all nine LCLs showed an increase in the % of GFP-positive cells which was significant (P Ͻ 0.004).
One of the potential reasons why LCLs are easier to infect once they have been stimulated by CD40L, is that CD51 is upregulated. We therefore analyzed the same LCLs for CD51 expression before and after 72 h of CD40L cross-linking. As shown in Figure 7b , the MFI of CD51 expression was significantly upregulated in 4/5 of the representative LCLs shown. These same LCLs (numbers 1, 2, 3 and 5) were the same ones as shown in Figure 7a which had an enhanced capacity for infection post CD40L cross-linking.
AdV infected LCLs have immunostimulatory capacity
To confirm that the AdV infected LCLs retained their immunostimulatory capacity, graded numbers of irradiated, infected or uninfected LCLs were mixed with allogeneic T cells and after 5 days, proliferation of the responder T cells was assessed. As shown in Figure 8a , the AdV infected LCLs were as active as uninfected LCLs in stimulating T cell proliferation. Phenotypically, the proliferating T cells were predominantly CD4
+ but there was also a significant percentage of CD8
+ T cells and a small percentage (Ͻ10%) of CD56 + NK cells in both infected and uninfected groups.
AdV infected LCLs are potent presenters of exogenous antigen
The AdV infected LCLs were compared with uninfected LCLs for their capacity to uptake, process and present tetanus toxoid (TT) to autologous, purified T lymphocytes from donors who were both EBV and AdV-seropositive. As shown in Figure 8b , at all of the T:LCL ratios tested, AdV infected LCLs stimulated the proliferation of autologous T cells significantly better than uninfected LCLs (P Ͻ 0.005). Phenotypically, the proliferating T cells were predominantly CD4
+ in both infected and uninfected groups but there was also a significant proportion of CD8 + T cells in both groups (Figure 8b ) and no CD56 + NK cells.
AdV infected LCLs can stimulate the simultaneous expansion of AdV and EBV-specific CTLs in vitro
To simultaneously expand CTLs which recognized both AdV and EBV-expressing target cells, AdV infected LCLs were co-cultured with autologous PBMNCs and stimulated weekly for 4-5 weeks. As autologous targets we used LCLs, AdV infected DCs and uninfected DCs. As allogeneic targets, HLA-mismatched LCLs, AdV infected and uninfected DCs were used in addition to HSB-2 which is a cell line susceptible to natural killer (NK) cell lysis. As shown in Figure 9a , the CTLs recognized only the autologous LCL target (48 Ϯ 7.4% at an E:T ratio of 40:1) and the AdV infected DC target (39 Ϯ 5.2% at an E:T ratio of 40:1) indicating that CTLs generated with this methodology had specificity for both EBV and AdV. There was no significant lysis of any of the other targets including HSB-2, indicating that the level of MHC-unrestricted killing was low in this system. To confirm that the specific lysis of the targets was MHC restricted, the autologous LCL and the AdV infected autologous DCs were incubated with monoclonal antibodies directed against either HLA class I or class II on their surface. Figure 9b illustrates that the addition of a pan HLA-ABC antibody reduced the level of specific lysis of the AdV infected DCs, from 39% to 4.7% at an E:T ratio of 40:1, whilst the addition of an antibody against HLA-DR, reduced the killing to 3.0%, indicating that the specific lysis was mediated by both CD8 + and CD4 + T cells. The pattern of inhibition of autologous LCL killing was very similar, with the class I antibody reducing the lysis from 50% to 6.5% and the class II antibody inhibiting the lysis from 50% to 11.7%.
Discussion
Post hematopoietic stem cell (SC) transplantation, in the face of severe immunosuppression, reactivation of viruses such as AdV and EBV is associated with significant morbidity and mortality. 1, 2, 15 The limitations of anti-viral chemotherapeutic agents and an increased understanding of the cellular immune response to viral pathogens. 16, 17 have prompted interest in developing adoptive immunotherapy for patients considered at high risk of developing viral complications.
Evidence that such an approach can be of significant benefit comes from the studies of Rooney et al, which demonstrate that adoptive transfer of in vitro generated EBVspecific CTLs to 39 pediatric patients who had received a T cell-depleted stem cell transplant, was effective in preventing EBV-LPD in 100% of cases. [8] [9] [10] For similar patients who did not receive EBV-specific CTLs, the inciBone Marrow Transplantation dence of EBV + lymphoma, in the first year post transplantation, was 11.5%. The polyclonal (CD4 + and CD8 + ) donorderived T cell lines specific for EBV proteins were shown to expand in vivo, to have powerful anti-viral effects and to persist for up to 38 weeks in regenerated lines. Importantly, infusion of these CTLs was not associated with any significant short-term or long-term side-effects, including graft-versus-host disease (GVHD). The most direct evidence that infused EBV-specific CTLs can restore anti-viral and anti-tumor immunity comes from the eradication of established EBV + lymphoma in two children who received a T cell-depleted graft and who did not receive prophylactic CTLs. 10 Therefore, it is apparent that restoration of cellular immunity towards EBV is critical in preventing EBV-LPD in the immunocompromised host. The association between severe AdV infection and immunosuppression strongly suggests that in a healthy individual, AdV, like EBV, is also controlled by the cellular arm of the immune response. 18, 19 Similar to other human pathogenic viruses, AdV has evolved several mechanisms to escape immune surveillance. [20] [21] [22] For example, the E1A region proteins block responses to interferons by modifying the IFN-induced transcription of anti-viral genes. In addition, adenoviral proteins encoded by the E3 promoter transcription unit, such as E3-gp19K which is located in the membrane of the endoplasmic reticulum, binds to MHC class I antigens of infected cells and prevents their export from the ER to the cell surface. Consequently, E3-gp19K blocks killing of infected cells by CD8 + CTLs; to date, there are no published reports demonstrating that AdV interferes with MHC class II expression or function. Therefore, if AdV-specific CTLs are to be used for adoptive transfer to transplant patients then a method needs to be developed which induces the generation of CD4 + CTLs. For those patients considered at low risk of developing EBV-LPD, but at significant risk of developing serious AdV infections, we generated AdV-specific CTLs using virally infected DCs 23 as the stimulator cells. DCs are specialized antigen-presenting cells 24, 25 which have the capacity to capture, process and present foreign antigens to naive or quiescent T cells, both in vitro and in vivo. 26, 27 These APCs express abundant MHC molecules, both class I and II, adhesion molecules as well as the costimulatory molecules CD80, CD86 and CD40 which are critical for T cell activation. Recent studies have shown that DCs exposed to specific antigens in the form of protein, peptides or RNA are capable of priming both CD8
+ and CD4 + tumor-and viralspecific CTLs in vitro and in vivo. [28] [29] [30] [31] [32] The ability of DCs to stimulate a naive T cell response would be a distinct advantage in the situation where the donor is AdV-seronegative. In order to circumvent problems of immune escape, an AdV which had been deleted of both the E3 and the E1A regions was used to infect the immature DCs. Post infection, the DCs were matured in the presence of TNF-␣ in a bid to optimize class II-restricted antigen presentation. Such a sequence of events was critical as, in a dosedependent manner, TNF-␣ downregulated the expression of the integrin receptor CD51 which is important for the internalization of the bound virus. To neutralize the CD51 integrin, we incubated the DCs with a specific anti-CD51 antibody prior to lipoadenofection. Such treatment inhibited viral infection by 40-50% and this partial neutralization is consistent with the potential involvement of a second receptor, the ␣ 5 ␤ 5 integrin, in adenovirus internalization. This downregulation of CD51 by TNF-␣ is one possible reason why mature DCs are more resistant to infection than immature ones.
The AdV-specific CTLs which were generated by our methodology were predominantly CD4
+ by phenotyping and the cytotoxic capacity of these T cells was confirmed using antibody blocking experiments. In contrast, Smith et al 13, 14 generated AdV-specific CTLs, using similar methodology, which were predominantly CD4 + by phenotyping but the majority of the specific cytotoxic activity was mediated by the CD8 + T cell fraction. In our system, two modifications may account for this observed difference: first, we complexed the AdV to lipofectamine prior to DC infection; and second, post infection exposed the infected immature DCs to a maturation signal prior to co-culture. Lipid-AdV complexes have been shown to be uptaken into DCs by both receptor-independent and -dependent endocytosis, the latter utilizing the coxsackie-AdV receptor (CAR) 32 and integrin receptors. [34] [35] [36] Antigen which is taken up via either of these routes can be introduced efficiently into the MHC class II pathway, and in the presence of a maturation signal, peptide-loaded class II molecules can fuse with the outer cell membrane, thereby depositing themselves on the cell surface. 37, 38 Therefore, by utilizing lipid in the infection step the DC can uptake the lipid-virus complex via both pathways whereas in the absence of lipid, the viral particles are taken up preferentially by receptor-dependent endocytosis. In addition, our mature DCs, post infection, express higher levels of MHC class II than do immature DCs.
In order to successfully expand two populations of CTLs simultaneously, considering that EBV and AdV are both strongly immunogenic, we considered it important to maximally express AdV antigens on the surface of LCLs. Under normal conditions, LCLs are difficult to infect efficiently with AdV therefore we developed a system in which the LCLs were pre-stimulated by CD40 cross-linking prior to infection. One of the possible reasons why such stimulation results in a higher rate of infection is that CD51 expression was significantly upregulated post cross-linking in the majority of the LCLs tested. Our study shows that these AdV infected LCLs have an equal immunostimulatory capacity to uninfected LCLs in the allogeneic setting and a stronger capacity to stimulate T cell proliferation in the autologous setting using donors with a high AdV load and a low EBV titer. The AdV-specific CTLs generated from these infected LCLs exclusively lysed the autologous targets expressing either AdV or EBV antigens and there was no significant lysis of HSB-2 indicating that the level of MHC-unrestricted killing was low in this system. Antibody blocking experiments confirmed that both the CD4 + and the CD8 + T cells were cytotoxic with the DC-AdV + targets being lysed more by the CD4 + T cells than by the CD8 + and the autologous LCL targets were lysed more by the CD8 + than by the CD4 + T cells. As explained above, we consider it an advantage that the AdV + targets are being lysed by CD4 + T cells as adenovirally infected cells in vivo escape CD8 + cytotoxic lysis due to downregulation of MHC class I molecules.
There are obvious advantages to generating 'bispecific' CTLs in vitro for adoptive transfer to the transplant patient. Our method is fairly easy and is feasible both in terms of resources and time. As compared to generating two separate CTL lines, the cost is lower and the cells can be expanded in FCS which is readily available at GMP grade, does not carry the risk of exposure to human pathogens, and is currently in use by other investigators using CTLs in clinical trials. Therefore, in summary, we have developed methodologies for generating both monospecific and bispecific anti-viral CTLs in vitro and we anticipate, in the future, that the safety and efficacy of such CTLs will be tested in phase I/II clinical trials.
